Fertility and Sterility
Volume 77, Issue 4 , Pages 669-673 , April 2002

Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome

  • Michael J Heard, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas USA
    • ,
  • Anita Pierce, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas USA
    • ,
  • Sandra A Carson, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas USA
    • ,
  • John E Buster, M.D.

      Affiliations

    • Corresponding Author InformationReprint requests: John E Buster, M.D., Baylor College of Medicine, 6550 Fannin S801A, Houston, Texas USA 77030 (FAX: 713-798-8231)
    • Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Baylor College of Medicine, Houston, Texas USA

Received 30 May 2001 ,Revised 22 October 2001 ,Accepted 22 October 2001.

References 

  1. Dunaif A, Futterweit W, Segal KR, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165–1174
  2. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520–527
  3. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992;41:1257–1266
  4. Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome (a review of therapeutic rationale and reproductive outcomes). Eur J Obstet Gynecol Reprod Biol. 2000;91:135–141
  5. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelezyk L. Metformin therapy dereases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73:1149–1154
  6. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999;72:282–285
  7. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, et al.  Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome (a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation). J Clin Endocrinol Metab. 2000;85:139–146
  8. Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol Metab. 1997;82:4075–4079
  9. Ehrmann DA, Cavaghan MK, Imperial J, Sturis J, Rosenfield RL, Polonsky KS. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524–530
  10. Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism. 1999;48:511–519
  11. Morin-Papunen C, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691–696
  12. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876–1880
  13. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion (a pilot study). Fertil Steril. 2001;75:46–52
  14. Seale FG, Robinson RD, Neal GS. Association of metformin and pregnancy in the polycystic ovary syndrome. J Reprod Med. 2000;45:507–510
  15. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene alone. Fertil Steril. 2001;75:310–315
  16. Rowe R, Comhaire F, Hargreave T. In: WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Female Partner. Cambridge: Press Syndicate of the University of Cambridge; 2000;p. 40–67
  17. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol. 1997;90:392–395
  18. Murafawa H, Hasegawa I, Kurabayashi T, Tanaka K. Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate. J Reprod Med. 1999;44:23–27
  19. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic pressure, while facilitating normal menses and pregnancy. Metabolism. 1999;43:647–654
  20. Elkind-Hirsch K, Chang J. Use of Insulin Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome. American Society for Reproductive Medicine Committee Opinion. 2000;(April):

PII: S0015-0282(01)03266-6

Fertility and Sterility
Volume 77, Issue 4 , Pages 669-673 , April 2002

Article Tools